Abstract
We have reviewed two Phase III clinical studies of isopropyl unoprostone conducted in Japan: a 12-week comparative study of 0.12% isopropyl unoprostone and 0.5% timolol, and a 52-week administration of two concentrations of isopropyl unoprostone in ocular hypertensive and primary open-angle glaucoma patients. These studies showed a similar ocular hypotensive effect of 0.12% isopropyl unoprostone to 0.5% timolol and a sustained ocular hypotensive effect of the drug for up to one year. Adverse reactions of isopropyl unoprostone were minor and similar to those of timolol. No pigmentary changes of the irides were noticed. In view of these results, isopropyl unoprostone seems to be a useful antiglaucoma medication.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase III
-
Comparative Study
-
Randomized Controlled Trial
MeSH terms
-
Administration, Topical
-
Adrenergic beta-Antagonists / administration & dosage
-
Adrenergic beta-Antagonists / adverse effects
-
Adrenergic beta-Antagonists / therapeutic use
-
Animals
-
Dinoprost / administration & dosage
-
Dinoprost / adverse effects
-
Dinoprost / analogs & derivatives*
-
Dinoprost / therapeutic use
-
Drug Evaluation
-
Follow-Up Studies
-
Glaucoma, Open-Angle / drug therapy*
-
Glaucoma, Open-Angle / physiopathology
-
Humans
-
Intraocular Pressure / drug effects
-
Ocular Hypertension / drug therapy*
-
Ocular Hypertension / physiopathology
-
Ophthalmic Solutions
-
Timolol / administration & dosage
-
Timolol / adverse effects
-
Timolol / therapeutic use
-
Treatment Outcome
Substances
-
Adrenergic beta-Antagonists
-
Ophthalmic Solutions
-
isopropyl unoprostone
-
Timolol
-
Dinoprost